Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
2005-05-24
2005-05-24
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C530S387300, C530S388850
Reexamination Certificate
active
06897044
ABSTRACT:
The present invention relates to a novel process for the preparation of biologically active antibody dimers in a pharmaceutically acceptable composition. The dimers can be composed of two antibody molecules having the same antigen binding specificity and linked through reducible, disulfide, or a non-reducible thioether, bond (homodimer). Alternatively, the dimers can be composed of two different antibody molecules having binding specificity for two distinct antigens (heterodimer). These dimers are useful for inducing hyper-cross-linking of membrane antigens. The present invention further relates to the use of biologically active antibody dimers for the preferential killing or inhibition of selected cell populations in the treatment of diseases such as cancer and autoimmune disorders.
REFERENCES:
patent: 5830698 (1998-11-01), Reff
patent: 6011138 (2000-01-01), Reff et al.
patent: WO 91 19515 (1991-12-01), None
patent: WO 9614339 (1996-05-01), None
patent: WO 9966951 (1999-12-01), None
Cruse et al., Illustrated Dictionary of Immunology. CRC Press. p. 19, 1995.*
The Pierce Catalog, pp. T-157, T163-T169, 1994-1995.*
Brenner et al. Science 229 81-883, 1985.*
Reff et al Blood 83 435-445, 1994.*
Fanger et al. Critical Reviews in Immunology 12 101-124, 1992.*
Paul. Fundamental Immunology, Raven Press, NY chapter 8, p. 242, 1993.*
Panka et al PNAS 85 3080-3084, 1988.*
Demidem A, et al., “Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs,”Cancer Biotherapy&Radiopharmaceuticals, 1997, 12(3):177-186.
Featherstone, “Bispecific antibodies: the new magic bullets,”Lancet, 1996, 348:536.
Ghetie M, et al., “Homodimerization of tumor-reactive monoclonal antibodies markedly Increases their ablility to induce growth arrest or apoptosis of tumor cells,”Proc. Natl. Acad. Sci. USA, 1997, 94: 7509-7514.
Hartmann, et al., “Treatment of Hodgkin's disease with bispecific antibodies,”Annals of Oncology 7(Suppl 4), 1996, S143-S146.
Kroesen, et al., “The role of apoptosis: a bispecific antibody-mediated T-cell cytotoxicity”,Br. J. Cancer, 1996, 73(6): 721-727.
Ring, et al., “Antigen forks: bispecific reagents that Inhibit cell growth by binding selected pairs of tumor antigens,”Cancer Immunology Immunotherapy, 1994, 39: 41-48.
Shan et al., “Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies,”Blood, 1998, 91(5): 1644-1652.
Shopes, “A genetically engineered huam IgG mutant with enhanced cytolytic activity,”J. Immun., 1992, 148(9): 2918-2922.
Snider et al., “Processing fate of protein antigen attached to IgD or MHC molecules on normal B lymphocytes using heterocrosslinked bispecific antibodies,”Molecular Immun., 1991, 28(7):779-788.
Brennan M, et al., “Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments,”Science, 1985, 229:81-3.
Chaouchi N, et al., “B cell antigen receptor-mediated apoptosis, Importance of accessory molecules CD19 and CD22, and of surface IgM cross-linking,”J. Immunol, 1995, 154:3096-104.
Clark EA, et al., “Role of the Bp35 cell surface polypeptide in human B-cell activation,”Proc Natl Acad Sci U S A, 1985, 82:1766-70.
Clark EA, et al., “Structure, function, and genetics of human B cell-associated surface molecules,”Adv Cancer Res, 1989, 52: 81-149.
FitzGerald K, et al., “Improved tumour targeting by disulphide stabilized diabodies expressed inPichia pastoris,”Protein Eng, 1997, 10: 1221-5.
Funakoshi S, et al., “Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas,”J. Immunother Emphasis Tumor Immunol, 1996, 19:93-101.
Hoider M, et al., “Engagement of CD20 suppresses apoptosis in germinal center B cells,”Eur. J. Immunol., 1995, 25:3160-64.
Hooijberg E, et al., “Enhanced antitumor effects of CD20 over CD19 monoclonal antibodies in a nude mouse xenograft model,”Cancer.Res., 1995, 55:840-6.
Jiang Liying et al., “Enhanced effector functions of dimeric forms of IDEC-C2B8 (rituximab),”Blood, 1999, 94(10):86a (Astract No. 376).
Maloney DG, et al., “Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma,”Blood, 1994, 84:2457-66.
Maloney et al., “IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma,”J Clin Oncol, 1997, 15(10):3266.
McLaughlin et al., “IDEC-C2B (rituximab): clinical activity in clinically chemoresistant (CCRD) low-grade of follicular lymphome (LG/F NHL) and in patients (pts) relapsing after anthracycline therapy (ANTRA-RX) of ABMT,”Proc. Am. Soc. Clin. Oncol., 1997, 16: 16a (Abstract 55).
McLaughlin et al., “Rituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Replased Indolent Lymphome: Half of Patients Respond to a Four-Dose Treatment Program,” J Clin Oncol., 1998, 16(8):2825-33.
Merchant AM et al., “An efficient route to human bispecific IgG,”Nature Biotechnology, 1998, 16(7):1087 (Abstract).
Newell MK, et al., “Ligation of major histocompatibility complex class II molecules mediated apoptotic cell death in resting B lymphocytes,”Proc Natl Acad Sci U S A, 1993, 90: 10459-63.
Press OW, et al., “Monoclonal antibody 1F5 (anit-CD20) serotherapy of human B cell lymphomas,”Blood, 1987, 69: 584-91.
Siegall CB, et al., “Cytotoxicity of chimeric (human-murine) monoclonal antibody BR96 IgG, F(ab′)2, and Fab′ conjugated toPseudomonas exotoxin,”Bioconjug Chem, 1992, 3:302-7.
Tedder TF, et al., “Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes,”Eur J Immunol, 1986, 16:881-7.
Tedder TF, et al., “CD20: a regulator of cell-cycle progression of B lymphocytes,”Immunol Today, 1994, 15:450-4.
Valentine MA, et al., “Rescue from anti-IgM-induced programmed cell death by the B cell surface proteins CD20 and CD40,”Eur J Immunol, 1992, 22: 3141-8.
Varadarajan et al., “Conjugation of Phenyl Isothiocyanate Derivatives of Carborane to Antitumor Antibody and In Vivo Localization of Conjugates in Nude Mice,”Bioconj. Chem., 1991, 2: 102-110.
Willner D, et al., “(6-Maleimidocaproyl)hydrazone of doxorubicin—a new derivative for the preparation of immunoconjugates of doxorubicin,”Bioconjug Chem, 1993, 4: 521-7.
Wolff EA, et al., “Monoclonal antibody homodimers: enhanced antitumor activity in nude mice,”Cancer Res, 1993, 53:2560-5.
Braslawsky Gary R
Hanna Nabil
Hariharan Kandasamy
Huynh Tri B
LaBarre Michael J
Biogen Idec Inc.
Helms Larry R.
Pillsbury & Winthrop LLP
LandOfFree
Production of tetravalent antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Production of tetravalent antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production of tetravalent antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3373249